Albrecht Lommatzsch1, Nicole Eter2, Christoph Ehlken3, Ines Lanzl4, Hakan Kaymak5, Alexander K Schuster6, Focke Ziemssen7. 1. Augenzentrum am St. Franziskus-Hospital, Münster, Deutschland. 2. Klinik für Augenheilkunde, Universitätsklinikum Münster, Münster, Deutschland. 3. Klinik für Ophthalmologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland. 4. Chiemsee Augen Tagesklinik, Prien, Deutschland. 5. Makula-Netzhaut-Zentrum, Düsseldorf-Oberkassel, Deutschland. 6. Augenklinik und Poliklinik, Universitätsmedizin Mainz, Mainz, Deutschland. 7. Department für Augenheilkunde Tübingen, Universitäts-Augenklinik, Elfriede-Aulhorn-Str. 7, 72076, Tübingen, Deutschland. Focke.Ziemssen@med.uni-tuebingen.de.
Abstract
BACKGROUND: Numerous studies have identified a lack of treatment adherence as an important factor that often conflicts with the necessary number of anti-VEGF injections and therefore a better functional result. OBJECTIVE: This article discusses approaches and possible measures to reduce the risk of late and infrequent intravitreal injections leading to the major issue of undertreatment. MATERIAL AND METHOD: In the course of an expert dialogue, relevant parameters of treatment adherence and variables were identified. Meaningful processes were structured and assigned to organizational areas. RESULTS: The compilation of meaningful measures enables practitioners to optimize their own implementation in different areas. Regular monitoring measures can identify the extent of treatment interruption and discontinuation. For specific indicators (treatments per time interval, longest pause interval, minimum coverage per unit time, delay) an effect on the development of visual function was demonstrated. Organizational measures, training of teams and referring physicians, redundant and iterative information transfer to patients have been proven in the experience of experts. The firm integration of these processes into the structures is facilitated by working with checklists. CONCLUSION: An optimization of the processes is possible to improve the adherence and the functional results; however, interventional studies showing how adherence and persistence can be increased in the German treatment setting are still lacking.
BACKGROUND: Numerous studies have identified a lack of treatment adherence as an important factor that often conflicts with the necessary number of anti-VEGF injections and therefore a better functional result. OBJECTIVE: This article discusses approaches and possible measures to reduce the risk of late and infrequent intravitreal injections leading to the major issue of undertreatment. MATERIAL AND METHOD: In the course of an expert dialogue, relevant parameters of treatment adherence and variables were identified. Meaningful processes were structured and assigned to organizational areas. RESULTS: The compilation of meaningful measures enables practitioners to optimize their own implementation in different areas. Regular monitoring measures can identify the extent of treatment interruption and discontinuation. For specific indicators (treatments per time interval, longest pause interval, minimum coverage per unit time, delay) an effect on the development of visual function was demonstrated. Organizational measures, training of teams and referring physicians, redundant and iterative information transfer to patients have been proven in the experience of experts. The firm integration of these processes into the structures is facilitated by working with checklists. CONCLUSION: An optimization of the processes is possible to improve the adherence and the functional results; however, interventional studies showing how adherence and persistence can be increased in the German treatment setting are still lacking.
Authors: Kelvin Yi Chong Teo; Nakul Saxena; Alfred Gan; Tien Y Wong; Mark C Gillies; Usha Chakravarthy; Chui Ming Gemmy Cheung Journal: Ophthalmol Retina Date: 2020-04-01
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Thomas A Ciulla; Mohan V Tatikonda; Yehya A ElMaraghi; Rehan M Hussain; Amanda L Hill; Julie M Clary; Eyas Hattab Journal: Retina Date: 2018-09 Impact factor: 4.256
Authors: Panos G Christakis; Elvira Agrón; Michael L Klein; Traci E Clemons; J Peter Campbell; Frederick L Ferris; Emily Y Chew; Tiarnan D Keenan Journal: Ophthalmology Date: 2019-11-26 Impact factor: 12.079
Authors: Adi Berliner Senderey; Tamar Kornitzer; Gabriella Lawrence; Hilla Zysman; Yael Hallak; Dan Ariely; Ran Balicer Journal: PLoS One Date: 2020-06-23 Impact factor: 3.240